Navigation Links
TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis
Date:11/14/2012

ROCKVILLE, Md., Nov. 14, 2012 /PRNewswire/ -- TissueGene, Inc. announced today that it has completed patient enrollment for a U.S. Phase II clinical trial of TG-C in patients suffering from severe osteoarthritis of the knee.  TG-C is a therapy that involves human allogeneic chondrocytes developed to produce the therapeutic protein TGF-beta1 to regenerate cartilage.

The randomized, double-blind, placebo-controlled study has been designed to evaluate the safety and efficacy of TG-C in patients with Grade 3 chronic degenerative joint disease (DJD) of the knee.  This multi-center study has been conducted at five hospitals and clinical research centers across the country specializing in orthopedics.  Patients have received an intra-articular injection of either TG-C or placebo to the damaged joint area.  Patients in this study are being followed for two years with the primary efficacy endpoint analysis being conducted once all patients have reached their one year follow-up.  In conjunction with this milestone, TissueGene's licensing partner, Kolon Life Science, Inc. has completed patient enrollment for a Phase IIb study of TG -C in Korea.  

"We are very pleased with the clinical progress of TG-C in both the US and Korea and look forward to reporting our Phase II data in 2013," stated Dr. Kwan Hee Lee, Chief Medical Officer of TissueGene.

About TissueGene, Inc.

TissueGene, Inc. is a Maryland-based biopharmaceutical company focused on developing novel regenerative therapies for the treatment of various orthopedic diseases.  TissueGene's proprietary technology employs a form of cell-mediated therapy to deliver therapeutic proteins to localized areas of damaged tissue.  The company is currently developing four product candidates for the regeneration of cartilage (TG-C), bone (TG-B), disc (TG-D), and nerve tissue (TG-N).  For more information, please visit http://www.TissueGene.com.

About Kolon Life Science, Inc.

Kolon Life Science, Inc. (KOSDAQ: 102940), a subsidiary company of Kolon Group, is a leading Korean-based biochemical company focused on pharmaceutical ingredients and environmental biochemicals.  Its pharmaceutical business division provides active pharmaceutical ingredients and pharmaceutical intermediates ranging from zaltoprofen and flurbiprofen to argatroban and voglibose.  For more information, please visit http://www.kolonls.co.kr.


'/>"/>
SOURCE TissueGene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
2. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
3. NuMe Health Completes $1.5 Million Series A Financing To Advance Its First Cobiotic™ Aimed At Helping Prediabetics Maintain Healthy Blood Glucose Levels
4. CryoLife Completes Acquisition of Hemosphere
5. Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals
6. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
7. Jazz Pharmaceuticals Completes EUSA Pharma Acquisition
8. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
9. Ablative Solutions Completes $5.3M Series A Financing
10. Quantum OPS Completes $1.05M In Series A Financing To Advance Surgical Devices
11. Spine Pain Management, Inc. Completes $500,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... BioTherapeutics Inc. ( Stealth ), a clinical-stage biopharmaceutical company ... additions to its senior leadership team: W. Douglas ... Daniel Geffken as interim Chief Financial Officer. In ... has been promoted to Chief Clinical Development Officer. ... Daniel to our management team, as both will be ...
(Date:1/19/2017)... , Jan. 19, 2017 Accuray Incorporated ... CyberKnife® and TomoTherapy® Systems continue to set the bar ... the highest composite overall user satisfaction rating among radiation ... Q4 2016 MD Buyline Market Intelligence Briefing™. The most ... highest composite ratings among industry peers for 11 of ...
(Date:1/19/2017)... RATON, Fla. , Jan. 19, 2017 /PRNewswire/ ... a medical device company specializing in the treatment ... such as keloids, with superficial radiation therapy, today ... and full year 2016 financial results on Thursday, February ... The Company will hold a conference call with ...
Breaking Medicine Technology:
(Date:1/21/2017)... Boca Raton, FL (PRWEB) , ... January 21, 2017 , ... ... from Germany, announced it is bringing its product to the United States as part ... perfected over the last 25 years, Alcovit aims to reduce the productions of nasty ...
(Date:1/21/2017)... Rosa, CA (PRWEB) , ... January 21, 2017 ... ... announce that Redwood Family Dermatology has recently joined their multi-specialty medical ... a full range of cosmetic services. , “We’re excited to add this excellent ...
(Date:1/20/2017)... ... 20, 2017 , ... A new partnership between Goodwill® and Roadie, Inc. aims ... need, from clothes to couches to dressers and bicycles. Roadie — the national on-the-way ... nearest Goodwill donation center through February 28th. , “January is an exciting time ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Lice Troopers, the ... cases in families with school-aged children since the holiday season. , “It happens ... with their families, sharing hugs and taking photos, which is the head-to-head gateway that ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin ... alternative VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic ... during your workout. , After a successful launch in Sweden last year, the ...
Breaking Medicine News(10 mins):